Literature DB >> 16372186

[Therapy strategies for advanced renal cell carcinoma].

M Staehler1, N Haseke, G Schöppler, T Stadler, C Adam, C G Stief.   

Abstract

The therapeutic regimen for metastatic renal cell cancer has changed substantially in the last years. Formerly, metastatic disease was regarded as being inoperable and had a disastrous prognosis. Nowadays, radical nephrectomy is the accepted urologic-oncologic standard therapy in metastatic primaries, if technically feasible. A complete resection of metastases may be curative, or can achieve a substantial palliative benefit. A better understanding of prognostic parameters helps in the selection of patients with a chance of benefiting from systemic immunochemotherapy. For patients with rapidly progressing tumors or sarcomatoid dedifferentiation, new effective chemotherapy regimens are available. New angiogenesis inhibitors such as sutent, avastin or sorafenib can potentially be effectively used in future therapeutic regimens.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16372186     DOI: 10.1007/s00120-005-0982-6

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  47 in total

Review 1.  Interferon in metastatic renal cell carcinoma.

Authors:  S D Fosså
Journal:  Semin Oncol       Date:  2000-04       Impact factor: 4.929

2.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

3.  Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.

Authors:  B I Rini; N J Vogelzang; M C Dumas; J L Wade; D A Taber; W M Stadler
Journal:  J Clin Oncol       Date:  2000-06       Impact factor: 44.544

4.  Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Français d'Immunothérape.

Authors:  B Escudier; C Chevreau; C Lasset; J Y Douillard; A Ravaud; M Fabbro; A Caty; J F Rossi; P Viens; J P Bergerat; J Savary; S Négrier
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

5.  Hepatic resection for metastatic renal tumors: is it worthwhile?

Authors:  A Alves; R Adam; P Majno; V Delvart; D Azoulay; D Castaing; H Bismuth
Journal:  Ann Surg Oncol       Date:  2003-07       Impact factor: 5.344

6.  A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma.

Authors:  Michael L Blute; Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke
Journal:  J Urol       Date:  2004-08       Impact factor: 7.450

Review 7.  Cancer statistics, 2004.

Authors:  Ahmedin Jemal; Ram C Tiwari; Taylor Murray; Asma Ghafoor; Alicia Samuels; Elizabeth Ward; Eric J Feuer; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2004 Jan-Feb       Impact factor: 508.702

Review 8.  [Regional immunotherapy of metastatic renal cell carcinoma].

Authors:  H Heinzer; E Huland; H Huland
Journal:  Urologe A       Date:  2002-05       Impact factor: 0.639

9.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

Authors:  Masahiro Fukuoka; Seiji Yano; Giuseppe Giaccone; Tomohide Tamura; Kazuhiko Nakagawa; Jean-Yves Douillard; Yutaka Nishiwaki; Johan Vansteenkiste; Shinzoh Kudoh; Danny Rischin; Richard Eek; Takeshi Horai; Kazumasa Noda; Ichiro Takata; Egbert Smit; Steven Averbuch; Angela Macleod; Andrea Feyereislova; Rui-Ping Dong; José Baselga
Journal:  J Clin Oncol       Date:  2003-05-14       Impact factor: 44.544

10.  Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

Authors:  Eric K Rowinsky; Garry H Schwartz; Jared A Gollob; John A Thompson; Nicholas J Vogelzang; Robert Figlin; Ronald Bukowski; Naomi Haas; Pamela Lockbaum; Yu-Ping Li; Rosalin Arends; Kenneth A Foon; Gisela Schwab; Janice Dutcher
Journal:  J Clin Oncol       Date:  2004-06-21       Impact factor: 44.544

View more
  3 in total

Review 1.  [Managing the side effects of angiogenetic inhibitors in metastatic renal cell carcinoma].

Authors:  M Staehler; N Haseke; G Schöppler; T Stadler; G Heinemann; C G Stief
Journal:  Urologe A       Date:  2006-10       Impact factor: 0.639

2.  Liver resection for metastatic disease prolongs survival in renal cell carcinoma: 12-year results from a retrospective comparative analysis.

Authors:  Michael D Staehler; Jessica Kruse; Nicolas Haseke; Thomas Stadler; Alexander Roosen; Alexander Karl; Christian G Stief; Karl W Jauch; Christiane J Bruns
Journal:  World J Urol       Date:  2010-05-04       Impact factor: 4.226

3.  [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].

Authors:  L M Ehmann; V Heinemann; A Wollenberg
Journal:  Internist (Berl)       Date:  2011-11       Impact factor: 0.743

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.